CASP3 and ovarian cancer: The 24-h administration of pyrimethamine did not trigger caspase-3 cleavage in ovarian cancer cells and the apoptotic signal was only observed at 48 or 72 h (Fig. 1B) or higher pyrimethamine concentrations (Fig. 1C).